Quantum Biopharma (QNTM) Stock Price, News & Analysis

Company Overview

Quantum BioPharma Ltd. (NASDAQ:QNTM) is a biotechnology company focused on developing treatments for neurodegenerative and inflammatory disorders, as well as alcohol and substance-use disorders. The company’s research programs are intended to address conditions for which existing treatment options may be limited.

Its lead development program is Lucid-MS, an investigational small-molecule therapy designed to protect or restore myelin, the insulating material surrounding nerve fibers. Quantum BioPharma has identified multiple sclerosis as a potential application for the program and continues to evaluate its broader potential in neurodegenerative diseases. The company also has research activities related to alcohol-use disorder and other central nervous system conditions.

Quantum BioPharma was formerly known as FSD Pharma Inc. and adopted its current name as part of a corporate rebranding. The company is based in Canada and conducts its business through research and development activities and related subsidiaries, including Lucid Psycheceuticals. Zeeshan Saeed serves as the company’s chief executive officer and president.

Key Stats

• Today's Range: $2.60 to $2.74
• 50-Day Range: $2.66 to $4.00
• 52-Week Range: $2.07 to $15.50
• Volume: 107,421 shs
• Average Volume: 207,783 shs
• Market Capitalization: $21.92 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.00
• Consensus Rating: Hold

Quantum Biopharma Stock Analysis - MarketRank™

Quantum Biopharma scored higher than 40% of companies evaluated by MarketBeat, and ranked 685th out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

Quantum Biopharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Quantum Biopharma has a consensus price target of $8.00, representing about 195.2% upside from its current price of $2.71.

Amount of Analyst Coverage

Quantum Biopharma has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Quantum Biopharma is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Quantum Biopharma is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Quantum Biopharma has a P/B Ratio of 2.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.88% of the float of Quantum Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Quantum Biopharma has a short interest ratio ("days to cover") of 1.59, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Quantum Biopharma has recently increased by 48.91%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Quantum Biopharma does not currently pay a dividend.

Dividend Growth

Quantum Biopharma does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.47

News Sentiment

Quantum Biopharma has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Quantum Biopharma this week, compared to 3 articles on an average week.

Search Interest

Only 3 people have searched for QNTM on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

7 people have added Quantum Biopharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Quantum Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

8.53% of the stock of Quantum Biopharma is held by insiders.

Percentage Held by Institutions

1.24% of the stock of Quantum Biopharma is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/15/2026
• Next Earnings (Estimated): 11/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:QNTM
• Previous Symbol: NASDAQ:QNTM
• CIK: 1771885
• Web: www.quantumbiopharma.com
• Phone: 416-854-8884
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Quantum Biopharma: $8.00
• High Price Target: $8.00
• Low Price Target: $8.00
• Potential Upside/Downside: +195.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.49)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$26.17 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -582.23%
• Return on Assets: -184.20%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.20
• Quick Ratio: 1.19

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.34 per share
• Price / Book: 2.02

Miscellaneous

• Outstanding Shares: 8,090,000
• Free Float: 7,397,000
• Market Cap: $21.92 million
• Optionable: N/A
• Beta: 0.39